CDER Guidance Agenda
CDER Guidance Agenda
The latest headlines across every section, pulled from official and open-access sources.
CDER Guidance Agenda
The World Health Organization (WHO) today released updated guidelines on reducing the risk of cognitive decline and dementia , providing countries with evidence-based recommendations to help prevent or delay the onset of dementia across the life course. Dementia is a condition caused by brain diseases and affects memory, thinking and the ability to function. More than 57 million people live with dementia worldwide and nearly 10 million people get newly diagnosed every year. Alzheimer disease is the most common form of dementia and is estimated to account for 60–70% of cases. While there…
Annual report and data tables showing how often bloodstream infections occur in critical care in England, the microbes that cause them, and linked factors.
Details of the organisations that are currently approved to undertake conformity assessments on medical devices.
Original new drug approval. tablet, oral. Sponsor: Msd
Failed Impurities/Degradation Specifications — ONESOURCE SPECIALTY PHARMA LIMITED · Class II · Ongoing · 4284 vials
Subpotent drug — Gasco Industrial Corp. · Class II · Ongoing · N/A
Subpotent drug — Gasco Industrial Corp. · Class II · Ongoing · N/A
Subpotent drug — Gasco Industrial Corp. · Class II · Ongoing · N/A
cGMP deviations — Shimoga Chemicals · Class II · Ongoing · N/A
Lack of Sterility Assurance — Reliance Life Sciences Private Limited · Class II · Ongoing · 5,020 vials
Subpotent drug — Gasco Industrial Corp. · Class II · Ongoing · N/A
Subpotent drug — Gasco Industrial Corp. · Class II · Ongoing · N/A
Lack of Sterility Assurance — Reliance Life Sciences Private Limited · Class II · Ongoing · 11,400 vials
Lack of Sterility Assurance — Reliance Life Sciences Private Limited · Class II · Ongoing · 12,000 vials
Lack of Sterility Assurance — Reliance Life Sciences Private Limited · Class II · Ongoing · 8,001 vials
Failed Impurities/Degradation Specifications; Formaldehyde levels exceeded specification. — BioMed Laboratories, LLC. · Class II · Ongoing · 509,652 tubes
Subpotent drug — Gasco Industrial Corp. · Class II · Ongoing · N/A
Failed Impurities/Degradation Specifications — QuVa Pharma, Inc. · Class II · Ongoing · N/A
Surgical dressing manufactured out of specification (greater thickness). — ConvaTec, Inc · Class II · Ongoing · 4230 units
Reduction in the on-board stability of the GSP GALT assay. This may increase the likelihood of run-QC failures and consequently delay the reporting of patient results. — WALLAC OY · Class II · Ongoing · 3,274 units
A product error defect may cause incorrect bracket placement. — Klowen Braces · Class II · Ongoing · 3 units
A software anomaly can occur when the pump is paired with the Instinct sensor. Under certain circumstances, the pump unexpectedly stops delivering insulin and displays two error messages back-to-back: Pump Error 53 followed immediately by Pump Error 23. Insulin delivery will stop which may lead to delayed therapy and an increased risk of hyperglycemia or … — Medtronic MiniMed, Inc. · Class II · Ongoing · 778
Olympus has developed and released newly designed version of the Distal Cover (MAJ-2315) to replace previous design of the Single Use Distal Covers. — Olympus Corporation of the Americas · Class II · Ongoing · 988700 units